FDA 483 - Sant P. Chawla, MD - June 30, 2026

An FDA inspection of Sant P. Chawla, M.D., Clinical Investigator, in Santa Monica, revealed significant deficiencies in the conduct of a clinical study. The firm failed to adhere to the study protocol's eligibility criteria for multiple subjects and did not maintain adequate and accurate case histories, with discrepancies found between source documents and the electronic data capturing system.